DC3138Canertinib dihydrochloride
Canertinib dihydrochloride (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM.
View activity & pricesDC Chemicals · Research reagentsDC3138 
DC7106
DC7383
DC7084
DC7006
DC7200
DC7342
DC7695
DC10796
DC1091
DC7225
DC7924
DC1075
DC7167
DC1070
DC8491
DC8472
DC8280
DC8608
DC7353
DC8852
DC10527
DC10739
DC10479
DC10282
DC10632
DC10828
DC11900
DC7993
DC11450
DC12072
DC10219
DC11543
DC4124
DC3164
DC2047
DC3139
DC8300
DC2103
Lung Cancer
39 products · Page 1 of 1
All small molecule research tools
DC3138DC7106Rociletinib (CO-1686)
Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.
View activity & pricesDC7383CH5424802(Alectinib)
The dissociation constant (KD) value of CH5424802 For ALK in an ATP-competitive manner is 2.4 nM. CH5424802 has substantial inhibitory potency against both native ALK and L1196M with Ki of 0.83 nM and 1.56 nM,…
View activity & pricesDC7084Nintedanib (BIBF 1120)
BIBF 1120 is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
View activity & pricesDC7006AZD-9291(Osimertinib)
Osimertinib (AZD-9291) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.
View activity & pricesDC7200Motesanib Diphosphate (AMG-706)
Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than…
View activity & pricesDC7342Foretinib(XL880)
Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
View activity & pricesDC7695Defactinib (VS-6063, PF-04554878)
Defactinib is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.
View activity & pricesDC10796Prexasertib (LY2606368)
Prexasertib (LY2606368) is a potent, selective and ATP-competitive checkpoint kinase 1 (Chk1) inhibitor, with an IC50 and a Ki of <1 nM and 0.9 nM, respectively.
View activity & pricesDC1091PF-299804 (Dacomitinib,PF-00299804)
Dacomitinib is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
View activity & pricesDC7225Pelitinib (EKB-569; WAY-EKB 569)
Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC50 of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282, 800, and 1255 nM, respectively.
View activity & pricesDC7924PF06463922(Lorlatinib)
Lorlatinib is a potent, dual ALK/ROS1 inhibitor, with Kis of 0.02 nM, 0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK-L1196M, respectively.
View activity & pricesDC1075AZD4547
AZD4547 is a potent inhibitor of the FGFR family with IC50s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
View activity & pricesDC7167Capmatinib(INCB28060)
Capmatinib (INCB28060) is a potent and selective c-MET kinase inhibitor. Capmatinib (INCB28060) inhibits c-MET kinase activity with an average IC50 of 0.13 nM.
View activity & pricesDC1070MK-1775(AZD-1775,Adavosertib)
Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.
View activity & pricesDC8491GSK2879552
GSK2879552 is an orally available, irreversible inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
View activity & pricesDC8472AZD-3759
AZD3759 is a potent, oral active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively.
View activity & pricesDC8280BLU-9931
BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with an IC50 of 3 nM.
View activity & pricesDC8608BIBF 1120 esylate
Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
View activity & pricesDC7353ABT-751(E 7010)
ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively.
View activity & pricesDC8852SW-044248
SW044248 is a non-canonical topoisomerase I inhibitor, and selectively toxic for certain non-small cell lung cancer (NSCLC) cell lines.
View activity & pricesDC10527Ciforadenant (CPI-444)
CPI-444 is a potent and selective inhibitor of A2A receptor (A2AR) induces antitumor responses.
View activity & pricesDC10739AZD4635
AZD4635 is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM.
View activity & pricesDC10479RX518(CK-101:EGFR-IN-3)
RX518(CK-101:EGFR-IN-3) is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, and the L858R…
View activity & pricesDC10282ML385
ML385 is a specific nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor with an IC50 of 1.9 μM.
View activity & pricesDC10632Sitravatinib (MGCD516)
Sitravatinib is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth with IC50 of 3980 nmol/Lin vitro: MGCD516 is superior to other multi-kinase inhibitors in inhibiting cell…
View activity & pricesDC10828LXH254
LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor.
View activity & pricesDC11900Lazertinib
Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung…
View activity & pricesDC7993Prexasertib (LY2606368) 2HCl
Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a potent and selective ATP competitive inhibitor of the Chk1 protein kinase, with IC50s of <1 nM and 8 nM for CHK1 and CHK2, respectively, and a Ki of 0.9 nM…
View activity & pricesDC11450Selpercatinib(LOXO-292)
Selpercatinib is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively[1].…
View activity & pricesDC12072Alflutinib (AST2818 mesylate)
AST2818 mesylate is an EGFR inhibitor.
View activity & pricesDC10219LY3023414
LY3023414 potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively.…
View activity & pricesDC11543Glumetinib
Glumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC50 of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin[1].
View activity & pricesDC4124ROSCOVITINE(Seliciclib)
Roscovitine is a potent and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
View activity & pricesDC3164BIBW2992-MA2 (Afatinib dimaleate)
Afatinib dimaleate is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.
View activity & pricesDC2047Crizotinib (PF-2341066)
Crizotinib is a potent inhibitor of c-Met and ALK with an IC50 of 11 nM and 24 nM in cell-based assays, respectively.
View activity & pricesDC3139Erlotinib hydrochloride
Erlotinib hydrochloride inhibits purified EGFR kinase with an IC50 of 2 nM.
View activity & pricesDC8300Entrectinib (RXDX-101)
Entrectinib is a potent and orally available Trk, ROS1, and ALK inhibitor; inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC50 values of 1, 3, 5, 12 and 7 nM, respectively.
View activity & pricesDC2103Gefitinib (ZD1839)
Gefitinib (ZD1839) is a EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells.
View activity & prices